Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Pfizer brands
GRN-529
Другие языки:

    GRN-529

    Подписчиков: 0, рейтинг: 0
    GRN-529
    GRN-529.svg
    Identifiers
    • (4-(Difluoromethoxy)-3-(pyridin-2-ylethynyl)phenyl)(5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)methanone
    CAS Number
    PubChem CID
    IUPHAR/BPS
    ChemSpider
    UNII
    Chemical and physical data
    Formula C22H15F2N3O2
    Molar mass 391.378 g·mol−1
    3D model (JSmol)
    • O=C(N1CC(C=CC=N2)=C2C1)C3=CC(C#CC4=CC=CC=N4)=C(OC(F)F)C=C3
    • InChI=1S/C22H15F2N3O2/c23-22(24)29-20-9-7-16(12-15(20)6-8-18-5-1-2-10-25-18)21(28)27-13-17-4-3-11-26-19(17)14-27/h1-5,7,9-12,22H,13-14H2
    • Key:JITMSIRHBAVREW-UHFFFAOYSA-N

    GRN-529 is a drug that was developed by Wyeth as a negative allosteric modulator of the metabotropic glutamate receptor 5 (mGluR5).

    A study conducted by Pfizer found that GRN-529 reduced repetitive behaviors without sedation and partially increased sociability in mouse models of autism.

    Another study conducted by Pfizer found a therapeutically relevant effect in animal models of depression. It is theorized to work by reducing glutamate receptor hyperactivity.

    See also

    External links

    • "GRN-529". Adis Insight. Springer Nature Switzerland AG.

    Новое сообщение